| |
| Biopharma segment |
|
 93.39 % |
of total Revenue |
| Opella Business |
|
1.04 % |
of total Revenue |
| Biopharma Dupixent |
|
33.64 % |
of total Revenue |
| Biopharma Aubagio |
|
0.51 % |
of total Revenue |
| Biopharma Industrial Sales |
|
1.03 % |
of total Revenue |
| Biopharma Polio Pertussis Hib Vaccines |
|
5.47 % |
of total Revenue |
| Biopharma Influenza Vaccines |
|
4.95 % |
of total Revenue |
| Biopharma RSV Vaccines Beyfortus |
|
3.81 % |
of total Revenue |
| Biopharma Meningitis Travel And Endemics Vaccines |
|
2.75 % |
of total Revenue |
| Biopharma Nexviazyme |
|
1.69 % |
of total Revenue |
| Biopharma Sarclisa |
|
1.26 % |
of total Revenue |
| Biopharma ALTUVIIIO |
|
2.48 % |
of total Revenue |
| Biopharma Rezurock |
|
1.05 % |
of total Revenue |
| Biopharma Cablivi |
|
0.58 % |
of total Revenue |
| Biopharma Xenpozyme |
|
0.49 % |
of total Revenue |
| Biopharma Tzield |
|
0.13 % |
of total Revenue |
| Europe |
|
19.63 % |
of total Revenue |
| Europe Biopharma segment |
|
19.63 % |
of total Revenue |
| Europe Biopharma Dupixent |
|
4.19 % |
of total Revenue |
| Europe Biopharma Aubagio |
|
0.14 % |
of total Revenue |
| Europe Biopharma Industrial Sales |
|
1.01 % |
of total Revenue |
| Europe Biopharma Polio Pertussis Hib Vaccines |
|
0.96 % |
of total Revenue |
| Europe Biopharma Influenza Vaccines |
|
1.19 % |
of total Revenue |
| Europe Biopharma RSV Vaccines Beyfortus |
|
1.29 % |
of total Revenue |
| Europe Biopharma Meningitis Travel And Endemics Vaccines |
|
0.45 % |
of total Revenue |
| Europe Biopharma Nexviazyme |
|
0.6 % |
of total Revenue |
| Europe Biopharma Sarclisa |
|
0.37 % |
of total Revenue |
| Europe Biopharma Rezurock |
|
0.04 % |
of total Revenue |
| Europe Biopharma Cablivi |
|
0.23 % |
of total Revenue |
| Europe Biopharma Xenpozyme |
|
0.19 % |
of total Revenue |
| Europe Biopharma Tzield |
|
0 % |
of total Revenue |
| United States |
|
47.47 % |
of total Revenue |
| United States Biopharma Dupixent |
|
24.7 % |
of total Revenue |
| United States Biopharma Aubagio |
|
0.29 % |
of total Revenue |
| United States Biopharma Industrial Sales |
|
0 % |
of total Revenue |
| United States Biopharma Polio Pertussis Hib Vaccines |
|
1.35 % |
of total Revenue |
| United States Biopharma Influenza Vaccines |
|
2.84 % |
of total Revenue |
| United States Biopharma Pharmaceuticals Segment |
|
47.47 % |
of total Revenue |
| United States Biopharma RSV Vaccines Beyfortus |
|
1.55 % |
of total Revenue |
| United States Biopharma Meningitis Travel And Endemics Vaccines |
|
1.54 % |
of total Revenue |
| United States Biopharma Nexviazyme |
|
0.84 % |
of total Revenue |
| United States Biopharma Sarclisa |
|
0.52 % |
of total Revenue |
| United States Biopharma ALTUVIIIO |
|
2.1 % |
of total Revenue |
| United States Biopharma Rezurock |
|
0.91 % |
of total Revenue |
| United States Biopharma Cablivi |
|
0.31 % |
of total Revenue |
| United States Biopharma Xenpozyme |
|
0.2 % |
of total Revenue |
| United States Biopharma Tzield |
|
0.13 % |
of total Revenue |
| Other Countries In Results Biopharma Dupixent |
|
4.75 % |
of total Revenue |
| Other Countries In Results Biopharma Aubagio |
|
0.08 % |
of total Revenue |
| Other Countries In Results Biopharma Industrial Sales |
|
0.02 % |
of total Revenue |
| Other Countries In Results Biopharma Polio Pertussis Hib Vaccines |
|
3.15 % |
of total Revenue |
| Other Countries In Results Biopharma Influenza Vaccines |
|
0.92 % |
of total Revenue |
| Other Countries In Results Biopharma Pharmaceuticals Segment |
|
26.29 % |
of total Revenue |
| Other Countries In Results Biopharma RSV Vaccines Beyfortus |
|
0.98 % |
of total Revenue |
| Other Countries In Results Biopharma Meningitis Travel And Endemics Vaccines |
|
0.76 % |
of total Revenue |
| Other Countries In Results Biopharma Nexviazyme |
|
0.25 % |
of total Revenue |
| Other Countries In Results Biopharma Sarclisa |
|
0.36 % |
of total Revenue |
| Other Countries In Results Biopharma ALTUVIIIO |
|
0.39 % |
of total Revenue |
| Other Countries In Results Biopharma Rezurock |
|
0.1 % |
of total Revenue |
| Other Countries In Results Biopharma Cablivi |
|
0.04 % |
of total Revenue |
| Other Countries In Results Biopharma Xenpozyme |
|
0.09 % |
of total Revenue |
| Other Countries In Results Biopharma Tzield |
|
0 % |
of total Revenue |
| Other |
|
1.04 % |
of total Revenue |
| Reportable Geographical Zones |
|
93.39 % |
of total Revenue |
| France |
|
3.66 % |
of total Revenue |
| Other Countries |
|
26.29 % |
of total Revenue |
| China |
|
5.61 % |
of total Revenue |
